The Presage® ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. (January 2013)

• Record Type: Journal Article
• Authors: Mueller, Thomas; Dieplinger, Benjamin
• Is Part Of: Expert review of molecular diagnostics. Volume 13:Number 1(2013)
• Page Start: 13
• Page End: 30
• Publication Date: 2013-01
• Subjects: acute coronary syndrome -- acute myocardial infarction -- asthma -- biomarker -- B-type natriuretic peptide -- cardiovascular disease -- chronic obstructive pulmonary disease -- emergency department -- heart disease -- heart failure -- IL-33 -- ILRL1 -- inflammation -- mortality -- natriuretic peptide -- outcome -- pneumonia -- prognosis -- sepsis -- ST2; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1586/erm.12.128
• Languages: English
• ISSNs: 1473-7159

Abstract

The Presage ® ST2 Assay (Critical Diagnostics, CA, USA) is an in vitro diagnostic device that quantitatively measures soluble suppression of tumorigenicity 2 (sST2) in serum and plasma by ELISA. This assay is US FDA approved and is indicated to be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. sST2 binds to IL-33 and functions as a 'decoy' receptor for IL-33, thereby attenuating the systemic effects of IL-33. Due to the role of IL-33/transmembrane isoform of suppression of tumorigenicity 2 signaling in cardiac remodeling, sST2 has emerged as a novel cardiovascular biomarker. In recent studies, it was shown that sST2 is a valuable predictor of several end points in heart failure, in acute coronary syndromes and in critically ill patients. In this review, analytical considerations and clinical applications of the Presage ST2 Assay will be discussed, as well as probable future concepts for adoption of sST2 measurements into clinical practice.